FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter referred to as FRONTEO) and Medical Corporation Seikakai Secodic Hospital (Location: Funabashi City, Chiba Prefecture, Director: Seiichiro Hoshi, hereinafter referred to as Secodic Hospital) will conduct joint research on the effectiveness verification of the fall prediction AI system "Coroban".

　Secomic Hospital is an affiliated hospital of the security company Secom, and is a regional core hospital with 530 employees, 292 licensed beds, and 28 clinical departments.We provide seamless medical care from the acute phase to the recovery phase and home care, with a rehabilitation ward, a community comprehensive care ward, an adjoining home nursing station, etc.

　The hospital introduced Coroban on a trial basis in 2019 and officially introduced it in 2020 with the aim of improving the quality of assessments and reducing the workload of nurses as part of measures to prevent falls among inpatients.In the joint research, we will measure and analyze the behavioral changes of nurses and the man-hour reduction effect required for assessment work due to the introduction of Coroban, and aim to build evidence of the effect of introducing Coroban.Specific items to be verified include changes in nurses' behavior after Coroban issues an alert about the risk of a patient falling, the effect of reducing incidents, changes in nursing work and awareness, and the creation of an assessment sheet realized by introducing the system. We are planning to shorten the time and fall prevention measures time.

　Falls and falls in the elderly are at risk of requiring long-term care, becoming bedridden, progressing to dementia, and even dying. One. Through research and development and provision of solutions for AI systems such as Coroban, which will help solve this problem, FRONTEO will solve problems at medical and nursing care sites, reduce the work burden of staff, improve the quality of care and the QOL of the elderly. We will continue to contribute to

　The impact of this matter alone on the business results for the current fiscal year is minor, but we will promptly notify you if there are any matters to be disclosed.

■ About Coroban　URL:https://lifescience.fronteo.com/aidevice/coroban/
Coroban is a fall prediction AI system developed by FRONTEO in collaboration with Eisai Inc. FRONTEO's natural language analysis AI "Concept Encoder (trademark: concept encoder, reading: concept encoder)" reads electronic medical records and evaluates the risk of falling from the patient's condition and nursing records.It is possible to make predictions with the same accuracy as the conventional fall / fall risk assessment sheet without increasing the burden on medical staff.Recommended by the Japan Fall Prevention Society.Patent registration number: Patent No. 6652986
* This system is not a medical device.This system predicts the risk of falls and is not intended for the judgment of doctors and nurses.

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO is a data analysis company that uses the in-house developed AI engines KIBIT and Concept Encoder, Looca Cross specialized in natural language processing to extract meaningful and significant information from a large amount of textual data and support companies' business. Since its inception in August 2003, we have been working globally with Japan, the United States, Korea, and Taiwan, mainly in the Legaltech business, such as e-discovery (electronic evidence disclosure) and digital forensic surveys, which support company international lawsuits. Based on AI technology developed in this project, we have expanded our business fields to life science, business intelligence, and economic security since 8, and have used AI to transform textual data into knowledge, thus contributing to the resolution of various companies' issues, including support for drug discovery, support for dementia diagnostics, and support for financial, human resources, and business. Listed on TSE Mothers (currently TSE Growth) on June 2014, 2007. In January 6, the company obtained a license to manufacture and sell Class I medical devices (license number: 26B2021X1), and in September of the same year, the company submitted a notification to sell controlled medical devices (notification number: 13MinatoMiSeikikiDai1). Capital: ¥10350 (as of March 9, 3).

* FRONTEO, KIBIT, conceptencoder, and Looca Cross are registered trademarks of FRONTEO in Japan.
* Coroban is a registered trademark of Eisai Co., Ltd. and FRONTEO.